長時間作用型ドラッグデリバリー技術およびサービス市場：世界の産業規模、動向、機会、予測、技術別、剤形別、使用材料別、流通チャネル別、地域別、競合別セグメント、2019年～2029年

長時間作用型ドラッグデリバリー技術およびサービスの世界市場規模は2023年に102億3,000万米ドルとなり、2029年までの予測期間のCAGRは10.34%で堅調な成長が予測されています。

長時間作用型ドラッグデリバリー技術およびサービスの世界市場は、徐放性製剤の需要増と患者の服薬アドヒアランス向上に牽引され、力強い成長を遂げています。この市場には、薬物の放出を延長して治療効果を高め、投与回数を減らすように設計されたさまざまな技術やサービスが含まれます。長時間作用型のドラッグデリバリー技術には、注射剤、インプラント、マイクロ粒子、経皮パッチなどがあり、長期間にわたる徐放性を提供します。これは、特に慢性疾患管理における従来の剤形の限界に対処するものです。同市場の成長を後押ししているのは慢性疾患の急増であり、薬剤の長期投与のための革新的なソリューションが必要とされています。長時間作用型製剤は患者のコンプライアンスを向上させ、頻繁な投与の負担を軽減し、治療成績の向上に貢献します。さらに、生分解性ポリマー、ナノテクノロジー、埋め込み型デバイスの進歩は、長時間作用型ドラッグデリバリーの機能をさらに拡大し、患者中心のアプローチを促進します。COVID-19パンデミックは、特にクリティカルケアシーンにおける持続的ドラッグデリバリーの重要性を浮き彫りにしました。このため、様々な治療領域における製剤の改良に重点を置き、この分野における研究開発が加速しています。製薬会社や製造受託機関は、長時間作用型ドラッグデリバリーシステムの開発、製造、試験のための専門的サービスを提供する上で重要な役割を果たしています。市場が進化し続ける中、製薬会社、研究機関、技術プロバイダー間の協力や提携がイノベーションを促進しています。このようなダイナミックな状況により、世界の市場情勢は医薬品の進歩の最前線に位置づけられ、薬剤の有効性、患者のコンプライアンス、全体的なヘルスケアの成果を向上させる有望なソリューションを提供しています。

市場促進要因

慢性疾患の有病率の上昇

患者のアドヒアランスと利便性の向上

個別化医療への注目

主な市場課題

複雑な開発プロセス

生体適合性と安全性への懸念

主要市場動向

移植可能なデバイスとデポ

ナノテクノロジーの進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（注射剤、ハイドロゲル、インプラント、マイクロニードル、ナノクリスタル懸濁液）
  • 剤形別（長時間作用型注射剤、長時間作用型埋め込み剤、局所/経皮剤、膣剤、その他）
  • 使用材料別（ポリマーベース、非ポリマーベース）
  • 流通チャネル別（病院・薬局、研究・学術機関、その他）
  • 企業別（2023年）
  • 地域別
• 市場マップ

第6章 北米の長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 剤形別
  • 使用材料別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 剤形別
  • 使用材料別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 剤形別
  • 使用材料別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 剤形別
  • 使用材料別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの長時間作用型ドラッグデリバリー技術およびサービス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 剤形別
  • 使用材料別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（該当する場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Adare Pharma Solutions
• Alkermes plc
• Camurus AB
• Corium, LLC.
• Creative Biolabs, Inc.
• Delpor, Inc.
• Durect Corporation
• Hanmi Pharm.Co.,Ltd.
• Integrated Bio Systems, Inc.
• Heron Therapeutics, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Long-Acting Drug Delivery Technologies and Services Market was valued at USD 10.23 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 10.34% through 2029. The Global Long-Acting Drug Delivery Technologies and Services Market is experiencing robust growth, driven by the increasing demand for extended-release formulations and improved patient adherence. This market encompasses a spectrum of technologies and services designed to prolong drug release, enhancing therapeutic efficacy and reducing the frequency of dosing. Long-acting drug delivery technologies include injectable depots, implants, microparticles, and transdermal patches, offering sustained release over an extended period. This addresses the limitations of traditional dosage forms, particularly in chronic disease management. The market's growth is propelled by a surge in chronic diseases, necessitating innovative solutions for prolonged drug administration. Long-acting formulations contribute to better patient compliance, reducing the burden of frequent dosing and enhancing treatment outcomes. Additionally, advancements in biodegradable polymers, nanotechnology, and implantable devices further expand the capabilities of long-acting drug delivery, fostering a patient-centric approach. The COVID-19 pandemic has underscored the importance of sustained drug delivery, particularly in critical care scenarios. This has accelerated research and development efforts in the field, with an emphasis on improving formulations for various therapeutic areas. Pharmaceutical companies and contract manufacturing organizations play a crucial role in offering specialized services for the development, manufacturing, and testing of long-acting drug delivery systems. As the market continues to evolve, collaborations and partnerships between pharmaceutical companies, research institutions, and technology providers drive innovation. This dynamic landscape positions the Global Long-Acting Drug Delivery Technologies and Services Market at the forefront of pharmaceutical advancements, offering promising solutions for improved drug efficacy, patient compliance, and overall healthcare outcomes.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The Global Long-Acting Drug Delivery Technologies and Services Market is profoundly influenced by the escalating prevalence of chronic diseases worldwide. Chronic conditions, encompassing a spectrum of ailments like diabetes, cardiovascular disorders, and neurodegenerative diseases, have witnessed a staggering increase, placing an unprecedented burden on healthcare systems globally. This surge in chronic diseases is a key driver propelling the demand for advanced drug delivery technologies capable of addressing the unique challenges posed by prolonged therapeutic regimens. Long-Acting Drug Delivery Technologies play a pivotal role in the management of chronic diseases by offering sustained and controlled release of medications over an extended period. The conventional approach of frequent dosing is often impractical and burdensome for patients with chronic conditions. Long-acting formulations enhance patient adherence by reducing the frequency of administration, improving convenience, and minimizing the likelihood of missed doses. This not only simplifies complex medication regimens but also contributes to more effective disease management. The prevalence of chronic diseases is further amplified by demographic shifts, such as an aging population and changes in lifestyle factors like sedentary behavior and poor dietary habits. As a result, the demand for innovative drug delivery systems that ensure consistent therapeutic levels becomes imperative for achieving optimal treatment outcomes. The COVID-19 pandemic has underscored the vulnerability of individuals with pre-existing chronic conditions, emphasizing the need for resilient healthcare solutions. Long-acting drug delivery technologies address this need by providing a foundation for personalized medicine, allowing tailored approaches to match the unique requirements of individual patients. Investments in research and development within the pharmaceutical industry are increasingly directed towards creating sophisticated long-acting formulations that not only enhance therapeutic efficacy but also minimize side effects and improve overall patient well-being. In this landscape, the Global Long-Acting Drug Delivery Technologies and Services Market emerges as a vital component in the ongoing efforts to confront the rising tide of chronic diseases, promising innovative solutions that align with the evolving needs of modern healthcare.

Enhanced Patient Adherence and Convenience

Enhanced patient adherence and convenience stand out as significant drivers shaping the trajectory of the Global Long-Acting Drug Delivery Technologies and Services Market. In the realm of chronic disease management, where consistent medication adherence is paramount for therapeutic success, long-acting drug delivery technologies play a transformative role in addressing adherence challenges. Patients with chronic conditions often face the burden of complex medication regimens, requiring multiple doses throughout the day. The intricate dosing schedules can lead to non-compliance, resulting in suboptimal treatment outcomes and increased healthcare costs. Long-acting drug delivery technologies, such as extended-release formulations, injectable depots, and implantable devices, offer a solution by providing sustained release of medications over an extended period. By reducing the frequency of dosing, long-acting formulations enhance patient convenience and adherence. This is particularly crucial in chronic diseases like diabetes, where maintaining consistent blood glucose levels is essential. Long-acting insulin formulations, for example, allow patients to manage their condition with fewer injections, minimizing disruptions to daily life and fostering a more patient-friendly approach to treatment. Convenience is a key factor influencing patient behavior, and long-acting drug delivery technologies address this by simplifying treatment regimens. Patients are more likely to adhere to medications that align with their daily routines, and the reduced need for frequent administration fosters a sense of autonomy and empowerment. This not only improves patient satisfaction but also contributes to better overall health outcomes. Moreover, the convenience offered by long-acting drug delivery systems extends beyond daily life to include healthcare settings. For healthcare providers, these technologies streamline treatment plans, reduce the need for frequent patient visits, and enhance overall healthcare efficiency. As the Global Long-Acting Drug Delivery Technologies and Services Market continues to evolve, the emphasis on enhanced patient adherence and convenience positions these technologies as integral components in the broader landscape of patient-centric care. The market's growth is indicative of a paradigm shift towards more accessible, user-friendly, and effective therapeutic solutions for individuals managing chronic conditions worldwide.

Focus on Personalized Medicine

The Global Long-Acting Drug Delivery Technologies and Services Market is undergoing a transformative shift driven by a pronounced focus on personalized medicine. This paradigm places emphasis on tailoring medical treatment to the individual characteristics of each patient, and within this context, long-acting drug delivery technologies play a pivotal role in advancing personalized therapeutic approaches. Personalized medicine recognizes the inherent variability among patients, accounting for factors such as genetic makeup, lifestyle, and specific disease characteristics. Long-acting drug delivery technologies offer a versatile platform for customization, allowing for the precise modulation of drug release profiles to match the unique requirements of individual patients. This approach ensures that therapeutic interventions are not only effective but also well-suited to the specific needs and responses of diverse patient populations. In the context of chronic diseases, where the Global Long-Acting Drug Delivery Technologies and Services Market finds significant application, personalization becomes crucial. Patients with chronic conditions often exhibit varying responses to medications, and factors such as metabolism and disease progression can differ markedly. Long-acting formulations permit the fine-tuning of drug release kinetics, optimizing treatment efficacy while minimizing side effects. The integration of biomarkers and diagnostics further enhances the personalization of long-acting drug delivery. By leveraging genetic information, pharmacogenomics, and other patient-specific data, healthcare providers can tailor drug regimens to maximize therapeutic benefits. For instance, a long-acting drug delivery system can be customized to release medications at a rate compatible with an individual's metabolic rate, ensuring a sustained and optimal therapeutic effect. The demand for personalized solutions within the Global Long-Acting Drug Delivery Technologies and Services Market is also fueled by the recognition that one-size-fits-all approaches may not be optimal for complex and diverse patient populations. As the industry continues to innovate and integrate personalized medicine principles, long-acting drug delivery technologies emerge as a cornerstone in providing targeted, efficient, and patient-centered therapeutic solutions, marking a significant step forward in the evolution of modern healthcare.

Key Market Challenges

Complex Development Process

The Global Long-Acting Drug Delivery Technologies and Services Market faces a formidable challenge in the form of a complex development process. Designing and developing these technologies involves a multifaceted journey characterized by intricate formulations, sophisticated materials, and advanced technologies. The complexity arises from the need to create drug delivery systems that ensure controlled and sustained release over extended periods, a critical requirement for managing chronic conditions effectively. The development process commences with extensive research to identify suitable formulations and materials that meet the specific requirements of the drug and the targeted therapeutic outcome. Formulating long-acting drug delivery systems demands a nuanced understanding of the drug's pharmacokinetics, its interaction with the chosen materials, and the desired release kinetics. Navigating the regulatory landscape adds an additional layer of complexity. The stringent regulatory requirements for safety, efficacy, and quality necessitate rigorous testing and validation throughout the development process. Different regions may have distinct regulatory frameworks, requiring companies to navigate a complex maze of compliance standards to gain market approval. Moreover, achieving the desired balance between prolonged drug release and minimizing potential side effects is a delicate task that demands iterative optimization. The development timeline is often protracted, leading to extended periods before these technologies can reach the market. In essence, the intricate development process poses a challenge in terms of time, resources, and expertise. Companies investing in the Global Long-Acting Drug Delivery Technologies and Services Market must navigate this complexity to bring innovative solutions to fruition, balancing scientific rigor, regulatory compliance, and economic viability throughout the development journey. Overcoming these challenges is crucial for realizing the market potential and delivering advanced therapeutic options that align with the evolving landscape of healthcare.

Biocompatibility and Safety Concerns

Biocompatibility and safety concerns constitute critical challenges in the development and adoption of Global Long-Acting Drug Delivery Technologies and Services. As these technologies aim for sustained drug release within the patient's body, ensuring compatibility with biological systems and mitigating potential safety risks is paramount. Biocompatibility, referring to the ability of a material to perform its intended function within a biological environment without causing harm, is a primary consideration. The materials used in long-acting drug delivery systems must not induce adverse reactions, inflammation, or immune responses. Biocompatibility issues can arise from the introduction of foreign materials, such as implants or polymers, triggering responses that compromise patient safety. Ensuring the long-term safety of these technologies is equally challenging. Extended drug release periods necessitate materials that remain stable over time, resisting degradation and unintended interactions with bodily tissues. Rigorous testing is essential to evaluate the long-term effects of these systems, as unforeseen complications may arise after prolonged exposure. Additionally, the potential for systemic toxicity or localized irritation poses safety concerns that must be thoroughly addressed during the development phase. Preclinical studies and clinical trials play a crucial role in identifying and mitigating any safety risks associated with these technologies. Balancing the need for sustained drug release with biocompatibility and safety considerations requires a meticulous approach, involving collaboration between pharmaceutical researchers, materials scientists, and regulatory bodies. Successfully addressing these concerns is essential for gaining regulatory approval and fostering confidence among healthcare professionals and patients, ensuring that long-acting drug delivery technologies contribute positively to patient outcomes without compromising safety.

Key Market Trends

Implantable Devices and Depots

Implantable devices and depots represent a transformative trend within the Global Long-Acting Drug Delivery Technologies and Services Market. These innovative technologies offer a solution to the challenges associated with frequent dosing in chronic disease management by providing sustained and controlled drug release over extended periods. Implantable devices, ranging from small reservoirs to sophisticated microchips, are surgically placed within the body, allowing for localized and prolonged administration of therapeutic agents. One notable application of implantable devices is in the field of contraception, where subdermal implants can provide long-term, reversible birth control. These devices release hormones slowly, offering a convenient alternative to daily or monthly contraceptive methods. In the realm of therapeutics, implantable depots are gaining traction, especially in oncology. Cancer patients often undergo chemotherapy, requiring frequent administrations. Implantable depots enable a continuous release of anticancer drugs, reducing the need for frequent injections and improving patient compliance. This approach not only enhances the efficacy of treatment but also minimizes side effects associated with fluctuating drug concentrations. The appeal of implantable devices and depots extends beyond convenience. They offer a localized delivery approach, reducing systemic exposure and potential side effects. Additionally, these technologies allow for the customization of drug release profiles, aligning with the principles of personalized medicine. As the Global Long-Acting Drug Delivery Technologies and Services Market evolves, the increasing focus on implantable devices and depots underscores a commitment to patient-centric care and the development of solutions that enhance treatment outcomes while minimizing the burdens associated with traditional drug delivery methods.

Advancements in Nanotechnology

Advancements in nanotechnology have emerged as a driving force in the evolution of the Global Long-Acting Drug Delivery Technologies and Services Market. Nanotechnology, operating at the nanoscale level (typically less than 100 nanometers), provides a powerful platform for the design and development of innovative drug delivery systems with precise control over drug release kinetics. In the context of long-acting drug delivery, nanotechnology facilitates the creation of nanoparticles and nanocarriers that can encapsulate therapeutic agents. These nano systems offer several advantages, including enhanced drug solubility, improved bioavailability, and targeted delivery to specific tissues or cells. The small size of nanoparticles allows for efficient transport across biological barriers, enabling drugs to reach their intended sites of action. One key application of nanotechnology in long-acting drug delivery is the development of nanoscale formulations that enable sustained release of medications. Nanoparticles can be engineered to release drugs gradually over an extended period, providing a continuous therapeutic effect. This is particularly beneficial in chronic disease management, where maintaining consistent drug levels is crucial for optimal outcomes. Moreover, nanotechnology enables the design of stimuli-responsive drug delivery systems. These smart nanocarriers can respond to specific physiological cues, such as changes in pH or temperature, triggering controlled drug release. Such responsive systems contribute to the overall efficiency of long-acting drug delivery by adapting to the dynamic conditions within the body. As the Global Long-Acting Drug Delivery Technologies and Services Market continues to progress, the integration of nanotechnology enhances the precision, efficacy, and safety of drug delivery systems. The versatility offered by nanoscale formulations positions them as a cornerstone in the development of next-generation therapeutic solutions, fostering a future where long-acting drug delivery is characterized by enhanced performance and patient benefits.

Segmental Insights

Technique Insights

Based on Technique, injectables segment dominated the Global Long-Acting Drug Delivery Technologies and Services Market in 2023. This is ascribed due to its efficacy in providing sustained release formulations. Injectable drug delivery ensures precise dosage administration and prolonged therapeutic effects, enhancing patient adherence and treatment outcomes. The rising prevalence of chronic diseases necessitates prolonged drug release, driving the demand for injectable long-acting formulations. Additionally, advancements in formulation technologies, such as microsphere and liposome encapsulation, contribute to the segment's dominance. The versatility, convenience, and consistent therapeutic benefits offered by injectable long-acting drug delivery systems position this segment at the forefront of shaping the global market.

Distribution Channel Insights

Based on distribution channel, hospitals and retail pharmacies segment dominated the Global Long-Acting Drug Delivery Technologies and Services Market in 2023. This is ascribed due to their central role in patient care and medication distribution. Hospitals deploy long-acting drug delivery technologies for inpatient treatments, ensuring sustained therapeutic effects. Retail pharmacies play a key role in dispensing long-acting formulations, promoting accessibility and patient adherence. These segments benefit from the increasing prevalence of chronic conditions, driving the demand for extended-release medications. Moreover, the collaborative efforts between healthcare providers and pharmacies strengthen their influence, making Hospitals and Retail Pharmacies pivotal players in shaping the landscape of global long-acting drug delivery technologies and services.

Regional Insights

The North America segment dominates the global Long-Acting Drug Delivery Technologies and Services market due to its advanced healthcare infrastructure, significant research and development investments, and a concentration of pharmaceutical companies. The region's mature regulatory frameworks facilitate efficient product approvals, instilling confidence. The well-informed patient population and healthcare professionals drive the demand for extended-release drug delivery solutions, solidifying North America's leadership in advancing and commercializing these technologies and services on a global scale.

Key Market Players

Adare Pharma Solutions

Alkermes plc

Camurus AB

Corium, LLC.

Creative Biolabs, Inc.

Delpor, Inc.

Durect Corporation

Hanmi Pharm.Co.,Ltd.

Integrated Bio Systems, Inc.

Heron Therapeutics, Inc.

Report Scope:

In this report, the Global Long-Acting Drug Delivery Technologies and Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Long-Acting Drug Delivery Technologies and Services Market, By Technique:

Injectables Hydrogels Implants Microneedles Nanocrystal Suspensions

Long-Acting Drug Delivery Technologies and Services Market, By Dosage Forms:

Long-acting Injectables Long-acting Implantable Topical / Transdermal Vaginal Other

Long-Acting Drug Delivery Technologies and Services Market, By Material Used:

Polymer based Non-polymer based

Long-Acting Drug Delivery Technologies and Services Market, By Distribution Channels:

Hospitals and Retail Pharmacies Research and Academics Others

Long-Acting Drug Delivery Technologies and Services Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Long-Acting Drug Delivery Technologies and Services Market.

Available Customizations:

Global Long-Acting Drug Delivery Technologies and Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Long-Acting Drug Delivery Technologies and Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technique (Injectables, Hydrogels, Implants, Microneedles, Nanocrystal Suspensions)
  • 5.2.2. By Dosage Forms (Long-acting Injectables, Long-acting Implantable, Topical / Transdermal, Vaginal, Other)
  • 5.2.3. By Material Used (Polymer based, Non-polymer based)
  • 5.2.4. By Distribution Channels (Hospitals and Retail Pharmacies, Research and Academics, Others)
  • 5.2.5. By Company (2023)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Long-Acting Drug Delivery Technologies and Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique
  • 6.2.2. By Dosage Forms
  • 6.2.3. By Material Used
  • 6.2.4. By Distribution Channels
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technique
      • 6.3.1.2.2. By Dosage Forms
      • 6.3.1.2.3. By Material Used
      • 6.3.1.2.4. By Distribution Channels
  • 6.3.2. Mexico Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technique
      • 6.3.2.2.2. By Dosage Forms
      • 6.3.2.2.3. By Material Used
      • 6.3.2.2.4. By Distribution Channels
  • 6.3.3. Canada Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technique
      • 6.3.3.2.2. By Dosage Forms
      • 6.3.3.2.3. By Material Used
      • 6.3.3.2.4. By Distribution Channels

7. Europe Long-Acting Drug Delivery Technologies and Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By Dosage Forms
  • 7.2.3. By Material Used
  • 7.2.4. By Distribution Channels
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By Dosage Forms
      • 7.3.1.2.3. By Material Used
      • 7.3.1.2.4. By Distribution Channels
  • 7.3.2. Germany Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By Dosage Forms
      • 7.3.2.2.3. By Material Used
      • 7.3.2.2.4. By Distribution Channels
  • 7.3.3. United Kingdom Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By Dosage Forms
      • 7.3.3.2.3. By Material Used
      • 7.3.3.2.4. By Distribution Channels
  • 7.3.4. Italy Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technique
      • 7.3.4.2.2. By Dosage Forms
      • 7.3.4.2.3. By Material Used
      • 7.3.4.2.4. By Distribution Channels
  • 7.3.5. Spain Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technique
      • 7.3.5.2.2. By Dosage Forms
      • 7.3.5.2.3. By Material Used
      • 7.3.5.2.4. By Distribution Channels

8. Asia-Pacific Long-Acting Drug Delivery Technologies and Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By Dosage Forms
  • 8.2.3. By Material Used
  • 8.2.4. By Distribution Channels
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By Dosage Forms
      • 8.3.1.2.3. By Material Used
      • 8.3.1.2.4. By Distribution Channels
  • 8.3.2. India Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By Dosage Forms
      • 8.3.2.2.3. By Material Used
      • 8.3.2.2.4. By Distribution Channels
  • 8.3.3. South Korea Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By Dosage Forms
      • 8.3.3.2.3. By Material Used
      • 8.3.3.2.4. By Distribution Channels
  • 8.3.4. Japan Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technique
      • 8.3.4.2.2. By Dosage Forms
      • 8.3.4.2.3. By Material Used
      • 8.3.4.2.4. By Distribution Channels
  • 8.3.5. Australia Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technique
      • 8.3.5.2.2. By Dosage Forms
      • 8.3.5.2.3. By Material Used
      • 8.3.5.2.4. By Distribution Channels

9. South America Long-Acting Drug Delivery Technologies and Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By Dosage Forms
  • 9.2.3. By Material Used
  • 9.2.4. By Distribution Channels
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By Dosage Forms
      • 9.3.1.2.3. By Material Used
      • 9.3.1.2.4. By Distribution Channels
  • 9.3.2. Argentina Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By Dosage Forms
      • 9.3.2.2.3. By Material Used
      • 9.3.2.2.4. By Distribution Channels
  • 9.3.3. Colombia Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By Dosage Forms
      • 9.3.3.2.3. By Material Used
      • 9.3.3.2.4. By Distribution Channels

10. Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By Dosage Forms
  • 10.2.3. By Material Used
  • 10.2.4. By Distribution Channels
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By Dosage Forms
      • 10.3.1.2.3. By Material Used
      • 10.3.1.2.4. By Distribution Channels
  • 10.3.2. Saudi Arabia Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By Dosage Forms
      • 10.3.2.2.3. By Material Used
      • 10.3.2.2.4. By Distribution Channels
  • 10.3.3. UAE Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By Dosage Forms
      • 10.3.3.2.3. By Material Used
      • 10.3.3.2.4. By Distribution Channels
  • 10.3.4. Egypt Long-Acting Drug Delivery Technologies and Services Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Technique
      • 10.3.4.2.2. By Dosage Forms
      • 10.3.4.2.3. By Material Used
      • 10.3.4.2.4. By Distribution Channels

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Adare Pharma Solutions
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Alkermes plc
• 14.3. Camurus AB
• 14.4. Corium, LLC.
• 14.5. Creative Biolabs, Inc.
• 14.6. Delpor, Inc.
• 14.7. Durect Corporation
• 14.8. Hanmi Pharm.Co.,Ltd.
• 14.9. Integrated Bio Systems, Inc.
• 14.10. Heron Therapeutics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer